Clinical Trials Browser

Terminated × OTHER × Nivolumab × Clear all

NCT04902040 2026-03-18

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Phase 1/2 Terminated

19 enrolled 11 charts

GenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Lung Neoplasms

NCT04904302 2026-03-16

Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer

Phase 2 Terminated

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT04785287 2026-03-03

Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies

Phase 1/2 Terminated

EndocrineGastrointestinalThoracic

Adrenal Gland Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Lung Neoplasms, Neoplasm Metastasis

NCT03366766 2026-02-20

Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer

Phase 2 Terminated

14 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT03425331 2026-01-08

Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC

Phase 2 Terminated

5 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT04966676 2026-01-08

ATLAS

Phase 2 Terminated

Carcinoma, Non-Small-Cell Lung

NCT04050462 2025-10-16

Nivolumab Combined With BMS-986253 in HCC Patients

Phase 2 Terminated

13 enrolled 13 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT05199285 2025-10-03

A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab

Phase 2 Terminated

Gastrointestinal

Carcinoma, Hepatocellular

NCT04057365 2025-08-13

Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)

Phase 2 Terminated

15 enrolled 8 charts

Gastrointestinal

Biliary Tract Neoplasms

NCT04611126 2025-08-12

T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer

Phase 1/2 Terminated

6 enrolled 11 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02681302 2025-07-25

CPIT001

Phase 1/2 Terminated

46 enrolled 13 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT03815942 2025-06-25

ADVANCE

Phase 1/2 Terminated

23 enrolled 11 charts

Intermediate Risk Prostate Cancer

NCT02446860 2025-06-06

ADAPTeR

Phase 2 Terminated

Carcinoma, Renal Cell

NCT03432741 2025-05-26

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Phase 1 Terminated

BreastDermatologicLymphoid

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone

NCT06003075 2025-04-30

Induction Chemo-Nivo in Unresectable Stage III NSCLC

Phase 2 Terminated

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04239040 2025-03-19

GVAX Plus Checkpoint Blockade in Neuroblastoma

Phase 1 Terminated

Neuroblastoma

NCT06884683 2025-03-19

NivoMet

Phase 2 Terminated

Carcinoma, Renal Cell

NCT03727061 2025-03-11

Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer

Phase 1 Terminated

5 enrolled 8 charts

Recurrent Head and Neck Carcinoma

NCT04901988 2025-02-27

DETECTION

Phase 2/3 Terminated

Melanoma

NCT04322643 2025-02-25

Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma

Phase 2 Terminated

4 enrolled 10 charts

Carcinoma, Transitional Cell

NCT03991130 2025-02-06

High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma

Phase 2 Terminated

DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis

NCT04967196 2024-12-10

Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma

Phase 1 Terminated

Melanoma

NCT04375527 2024-12-04

Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma

Phase 2 Terminated

Melanoma

NCT03539198 2024-11-14

Study of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer

Head and Neck Neoplasms

NCT04270864 2024-10-18

PRIMO

Phase 1 Terminated

Advanced Cancer

NCT04431635 2024-09-27

Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma

Phase 1 Terminated

Indolent Lymphoma

NCT05200143 2024-09-19

Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma

Phase 2 Terminated

4 enrolled 11 charts

Melanoma

NCT03552380 2024-09-03

Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma

Phase 2 Terminated

12 enrolled 16 charts

Carcinoma, Renal Cell

NCT04159896 2024-07-16

ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer

Phase 2 Terminated

10 enrolled 8 charts

Prostatic Neoplasms

NCT03631641 2024-07-01

Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy

Phase 2 Terminated

3 enrolled 5 charts

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis

NCT02949843 2024-06-28

Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations

Phase 2 Terminated

19 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT05116917 2024-05-28

INFLUENCE

Phase 2 Terminated

Gastrointestinal

Influenza, Human, Pancreatic Neoplasms

NCT04655157 2024-05-23

QUAD01

Phase 1/2 Terminated

2 enrolled 12 charts

Melanoma

NCT03562507 2024-05-20

ERICA

Phase 2 Terminated

8 enrolled 11 charts

Carcinoma, Renal Cell, Neoplasm Metastasis

NCT03502746 2024-05-14

Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma

Phase 2 Terminated

34 enrolled 11 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT02621515 2024-05-06

CA209-322

Phase 2 Terminated

CNSDermatologic

Brain Neoplasms, Melanoma

NCT04429321 2024-04-26

Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary

Phase 1 Terminated

Carcinoma, Renal Cell

NCT02978443 2024-04-04

A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab

Phase 2 Terminated

14 enrolled 12 charts

Melanoma

NCT02992964 2024-04-02

Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers

Phase 1/2 Terminated

Turcot syndrome

NCT04610658 2024-04-02

Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC

Phase 1 Terminated

Small Cell Lung Carcinoma

NCT04899921 2024-03-26

Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets

Phase 2 Terminated

Melanoma

NCT03519308 2024-03-15

A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer

Phase EARLY_PHASE1 Terminated

3 enrolled 13 charts

Gastrointestinal

Pancreatic Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT03812562 2024-02-21

Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection

Phase EARLY_PHASE1 Terminated

Gastrointestinal

Carcinoma, Hepatocellular

NCT03495713 2024-01-17

Lymphoma RadVax LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS

Phase 2 Terminated

7 enrolled 7 charts

Hodgkin Disease

NCT03420521 2024-01-09

Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors

Phase 2 Terminated

9 enrolled 17 charts

Carcinoid Tumor, Neuroendocrine Tumors

NCT02831933 2023-09-21

ENSIGN

Phase 2 Terminated

11 enrolled 9 charts

DermatologicThoracic

Uveal Melanoma, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT05435053 2023-09-15

CHECKPOINT

Phase 2 Terminated

Gastrointestinal

Pancreatic Neoplasms

NCT04119336 2023-08-21

Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma

Phase 2 Terminated

2 enrolled 6 charts

Multiple Myeloma

NCT04185311 2023-08-15

Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted

Phase 1 Terminated

Breast Carcinoma In Situ, Triple Negative Breast Neoplasms